News articles about Tonix Pharmaceuticals (NASDAQ:TNXP) have been trending positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of 0.39 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.0291642180736 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Several brokerages have weighed in on TNXP. ValuEngine downgraded Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Aegis reaffirmed a “buy” rating on shares of Tonix Pharmaceuticals in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $8.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) traded up $0.03 during trading hours on Tuesday, hitting $3.40. The stock had a trading volume of 18,747 shares, compared to its average volume of 88,398. Tonix Pharmaceuticals has a 52-week low of $2.85 and a 52-week high of $9.40. The firm has a market cap of $26.29, a PE ratio of -1.01 and a beta of 3.09.

In other news, Director Ernest Mario sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $3.57, for a total transaction of $35,700.00. Following the sale, the director now directly owns 10,000 shares in the company, valued at approximately $35,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 48,934 shares of company stock worth $172,496 over the last 90 days. Insiders own 4.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Favorable Media Coverage Somewhat Unlikely to Affect Tonix Pharmaceuticals (TNXP) Share Price” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/13/favorable-media-coverage-somewhat-unlikely-to-affect-tonix-pharmaceuticals-tnxp-share-price.html.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.